Our preclinical findings lay the foundation for targeting p21+CD86+ microglia as a novel therapeutic strategy, highlighting the potential of exosome‐based senolytic anti‐inflammatory therapy for stroke and other central nervous system disorders. This evidence concerns the gene CDKN1A and stroke disorder.